Why Gossamer Bio, Inc.’s (GOSS) Stock Is Up 6.99%
As of Wednesday, October 21, Gossamer Bio, Inc.’s GOSS share price has surged by 6.99%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Commentary & Analysis
Why Gossamer Bio, Inc.’s (GOSS) Stock Is Up 5.10%
As of Tuesday, October 20, Gossamer Bio, Inc.’s GOSS share price has surged by 5.10%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Gossamer Bio, Inc.’s (GOSS) Stock Is Up 6.79%
As of Tuesday, October 13, Gossamer Bio, Inc.’s GOSS share price has surged by 6.79%, which has investors questioning if this is right time to sell.Michael Rose
Why Gossamer Bio, Inc.’s (GOSS) Stock Is Down 5.07%
As of Thursday, October 01, Gossamer Bio, Inc.’s GOSS share price has dipped by 5.07%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Gossamer Bio, Inc.’s (GOSS) Stock Is Up 5.14%
As of Wednesday, September 30, Gossamer Bio, Inc.’s GOSS share price has surged by 5.14%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | GOSS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $57.9 | $229.3 | 18% |
|
| Shares Out (Mil) | 4.1 | 53.4 | 13% |
|
| Institutional Ownership | 97.5% | 92.9% | 74% |
|
| Float (Mil) | 3.8 | 41.4 | 10% |
|
| Beta | 2.00 | 0.94 | 92% |
|
| Avg Daily Volume (000s) | 244 | 533 | 48% |
|
| Price Change (52-week) |
(94.6%) | 47.5% | 4% |
|
| Growth | GOSS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 6.9% | (10.1%) | 50% |
|
| EPS (5yr) | 26.8% | 15.8% | 78 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (15.7%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 4 | 5 | |
| Current EPS | ($3.934) | ($18.010) | ($15.612) | |
| Month Ago EPS | ($3.888) | ($16.320) | ($15.616) | |
| # Rev Up | 3 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($5.863) | ($31.909) | ($7.383) | |
| Year/Year Chg | (35.8%) | (69.8%) | (72.7%) | |
| Financials | GOSS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $53 | $37 | 20% |
|
| Net Income (TTM) (Mil) | ($125) | ($44) | 9% |
|
| EPS (TTM) | ($39.494) | ($1.600) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($163) | ($34) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $15 | $3 | 59% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $4 | 22% |
|
| Enterprise Value (Q1) (Mil) | $49 | $179 | 16% |
|
| Valuation | GOSS | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.17 | na |
|
| P/E | na | 20.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | GOSS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 66.0% | 96% |
|
| Net Margin | (235.0%) | (75.3%) | 4% |
|
| ROA | (78.8%) | (47.1%) | 7% |
|
| ROE | 178.7% | (53.5%) | 98% |
|
| Liabilities to Assets | 222.3% | 29.3% | 99% |
|
| F-Score | 2 | 2 | 7% |
|
Gossamer Bio, Inc. did not pass any screens on 10/21/2026.
